|By Marketwired .||
|June 9, 2014 05:06 PM EDT||
TORONTO, ONTARIO -- (Marketwired) -- 06/09/14 -- Primera Bioscience Research Inc. ("Primera" or the "Company") is pleased to announce that further to its news release of May 20, 2014, it has completed the acquisition of Copenhagen Minerals Inc. ("CMI") in a share purchase transaction (the "Acquisition"). As a result, the Company now owns a 100% interest in the Storo Gold Project, an exploration project located in Greenland. The Company's name will be changed to "Greenland Resources Inc." to reflect this Acquisition.
The Company also announces the appointment of Ruben Shiffman, Jesper Kofoed, and Leonard Asper to the board of directors, the appointment of Mr. Shiffman as Chairman, and Mr. Kofoed as CEO, effective June 5, 2014. Dennis Waddington will continue as Chief Financial Officer and Corporate Secretary.
The Company also announces the resignations of Carolyn J. Rayfield as director and CEO, and of Maria Bruzzese and Christine Davison as directors. Primera thanks Ms. Rayfield, Ms. Bruzzese and Ms. Davison for their contributions to the Company during their respective tenures. We wish them well in their future endeavours.
Pursuant to the acquisition of CMI, the following individuals acquired common shares of the Company ("Shares") at a deemed price of $0.10 per Share: Mr. Shiffman of 80 Richmond St. W., Toronto, Ontario, M5H 2A4, acquired ownership of 6,550,000 Shares; Mr. Asper of 35 Hazelton Ave., 2nd Floor, Toronto, Ontario, M5R 2E3, acquired control over 5,550,000 Shares; and Mr. Kofoed of 80 Richmond St. W., Toronto, Ontario, M5H 2A4, acquired 4,550,000 Shares. None of Messrs. Shiffman, Asper, or Kofoed held shares of the Company prior to the Acquisition. Upon completion of the Acquisition, the respective shareholdings of Messrs. Shiffman, Asper, and Kofoed represent approximately 31.2%, 26.4%, and 21.6% of the outstanding Shares. Each of these Share acquisitions was completed for investment purposes, and none of Messrs. Shiffman, Asper, or Kofoed have any current intention to increase the beneficial ownership of, or control or direction over, securities of the Company. The Company is relying on an exemption from the prospectus requirement set out in section 2.16 of National Instrument 45-106, which relates to distributions in connection with a take-over bid.
ON BEHALF OF THE BOARD OF DIRECTORS
For more information, or to obtain a copy of the applicable securities reports filed in connection with the matters set forth above, please contact Ruben Shiffman.
Primera Bioscience Research Inc.
Jul. 7, 2015 07:30 AM EDT Reads: 2,009
Jul. 7, 2015 07:15 AM EDT Reads: 1,860
Jul. 7, 2015 07:00 AM EDT Reads: 3,066
Jul. 7, 2015 07:00 AM EDT Reads: 1,056
Jul. 7, 2015 07:00 AM EDT Reads: 1,813
Jul. 7, 2015 06:45 AM EDT Reads: 2,375
Jul. 7, 2015 06:45 AM EDT Reads: 1,963
Jul. 7, 2015 04:00 AM EDT Reads: 2,529
Jul. 7, 2015 03:45 AM EDT Reads: 2,870
Jul. 7, 2015 02:00 AM EDT Reads: 1,324
Jul. 7, 2015 01:15 AM EDT Reads: 976
Jul. 6, 2015 11:00 PM EDT Reads: 1,949
Jul. 6, 2015 07:45 PM EDT Reads: 1,654
Jul. 6, 2015 07:00 PM EDT Reads: 1,222
Jul. 6, 2015 05:30 PM EDT Reads: 1,265